Expanded Access of Cabozantinib in Medullary Thyroid Cancer

Exclusion criteria

• ✕. to the thoracic cavity, abdomen, or pelvis within 12 weeks before the first dose of study treatment , or has ongoing complications or is without complete recovery and healing from prior radiation therapy
• ✕. to bone or brain metastasis within 14 days before the first dose of cabozantinib
• ✕. to any other site(s) within 28 days before the first dose of cabozantinib
• ✕. clinically-significant GI bleeding within 6 months before the first dose of cabozantinib
• ✕. hemoptysis of \> 0.5 teaspoon (2.5 ml) of red blood within 3 months before the first dose of cabozantinib
• ✕. any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of cabozantinib